PMID- 32140079
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220413
IS  - 1478-7547 (Print)
IS  - 1478-7547 (Electronic)
IS  - 1478-7547 (Linking)
VI  - 18
DP  - 2020
TI  - Economic evaluation of dapagliflozin versus metformin in Chinese patients whose 
      diabetes is inadequately controlled with diet and exercise.
PG  - 12
LID - 10.1186/s12962-020-00208-w [doi]
LID - 12
AB  - BACKGROUND: To investigate the long-term economic outcome of dapagliflozin versus 
      metformin in Chinese patients with type 2 diabetes mellitus (T2DM) whose diet and 
      exercise have not provided sufficient glycemic control. METHODS: An economic 
      analysis of dapagliflozin versus metformin was conducted by using the Chinese 
      Outcomes Model for T2DM with a time horizon of lifetime, which was developed and 
      validated based on the Chinese population. The efficacy data of lowering HbA1c of 
      dapagliflozin and metformin was derived from a network meta-analysis. Other 
      clinical, cost and utility inputs were obtained from published sources. Lifetime 
      discounted quality-adjusted life-years, cost, and incremental cost-effectiveness 
      ratio were measured. The uncertainty was facilitated by one-way and probabilistic 
      sensitivity analyses. RESULTS: The comparison of metformin and dapagliflozin in 
      Chinese patients with insufficient glycemic control by diet and exercise showed 
      that dapagliflozin was more costly and produced fewer health benefits in our 
      simulated cohort. The sensitivity analyses indicated that the results were 
      robust. CONCLUSIONS: Dapagliflozin is not likely to be cost-effective compared 
      with metformin for Chinese patients with T2DM inadequately controlled with diet 
      and exercise.
CI  - (c) The Author(s) 2020.
FAU - Nian, Hua
AU  - Nian H
AD  - 1Department of Pharmacy, Yueyang Hospital of Integrated Traditional Chinese and 
      Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 
      China. GRID: grid.412540.6. ISNI: 0000 0001 2372 7462
FAU - Wan, Xu
AU  - Wan X
AD  - 2Medical Decision and Economic Group, Department of Pharmacy, Ren Ji Hospital, 
      South Campus, School of Medicine, Shanghai Jiaotong University, Jiangyue Road 
      2000, Shanghai, China. GRID: grid.16821.3c. ISNI: 0000 0004 0368 8293
FAU - Ma, Jing
AU  - Ma J
AD  - 3Department of Endocrinology, Ren Ji Hospital, South Campus, School of Medicine, 
      Shanghai Jiaotong University, Shanghai, China. GRID: grid.16821.3c. ISNI: 0000 
      0004 0368 8293
FAU - Jie, Fu
AU  - Jie F
AD  - 2Medical Decision and Economic Group, Department of Pharmacy, Ren Ji Hospital, 
      South Campus, School of Medicine, Shanghai Jiaotong University, Jiangyue Road 
      2000, Shanghai, China. GRID: grid.16821.3c. ISNI: 0000 0004 0368 8293
FAU - Wu, Bin
AU  - Wu B
AUID- ORCID: 0000-0002-6696-7471
AD  - 2Medical Decision and Economic Group, Department of Pharmacy, Ren Ji Hospital, 
      South Campus, School of Medicine, Shanghai Jiaotong University, Jiangyue Road 
      2000, Shanghai, China. GRID: grid.16821.3c. ISNI: 0000 0004 0368 8293
LA  - eng
PT  - Journal Article
DEP - 20200228
PL  - England
TA  - Cost Eff Resour Alloc
JT  - Cost effectiveness and resource allocation : C/E
JID - 101170476
PMC - PMC7048053
OTO - NOTNLM
OT  - Chinese setting
OT  - Cost-effectiveness
OT  - Dapagliflozin
OT  - Metformin
OT  - Type 2 diabetes mellitus
COIS- Competing interestsThe authors declare that they have no competing interests.
EDAT- 2020/03/07 06:00
MHDA- 2020/03/07 06:01
PMCR- 2020/02/28
CRDT- 2020/03/07 06:00
PHST- 2018/10/19 00:00 [received]
PHST- 2020/02/23 00:00 [accepted]
PHST- 2020/03/07 06:00 [entrez]
PHST- 2020/03/07 06:00 [pubmed]
PHST- 2020/03/07 06:01 [medline]
PHST- 2020/02/28 00:00 [pmc-release]
AID - 208 [pii]
AID - 10.1186/s12962-020-00208-w [doi]
PST - epublish
SO  - Cost Eff Resour Alloc. 2020 Feb 28;18:12. doi: 10.1186/s12962-020-00208-w. 
      eCollection 2020.